HIGHLIGHTS
- who: Haipeng Wang from the Birla Institute of Technology and Science, India, China have published the paper: Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies, in the Journal: (JOURNAL) of 21/03/2022
- what: The meta-analysis was designed to investigate the effect of empagliflozin on diffuse myocardial fibrosis using CMR T1 mapping techniques. Differences in the study types (RCTs and cohorts) may be one of the reasons for the differences in results of ECV and T1. In the further, more studies focusing on the mechanism still need . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.